| Patient | Ray Charles |
|---|---|
| Date of birth | 1930-09-23 |
| Identifiers | MRN HR-ML009-SYN-TD; SSN (made up) 000-09-5561 |
| Document date | 1996-10-06 |
| Author | Gloria Fenwick, MD |
| Custodian | St. Posthumous Health Center |
Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.
Subsequent annual wellness visit; no new concerns. [S]
Mr. Charles is a 66-year-old man, blind since childhood, with an opioid use disorder in sustained remission for more than thirty years, who comes for his subsequent annual wellness visit five weeks after his six-month review. He has had no falls, emergency visits, or hospital stays this year. He continues to perform and travel. He has had no opioid or other drug use and reports no cravings; the naloxone spray is in date, at home and in his travel bag. The written plan for any future pain is saved on his phone. His eyes have been comfortable, with no pain, redness, or discharge. He reads his visit summaries and results with his screen reader and has had no trouble with his medicine labels. He has no new concerns. [S]
| Element | Detail |
|---|---|
| Visit | Subsequent annual wellness visit, age 66 |
| Safety events | No falls, emergency visits, or hospital stays this year |
| Recovery | Sustained remission; no cravings; naloxone in date at home and when traveling |
| Medicines | Naloxone nasal spray for emergencies only; no other prescription or over-the-counter medicines |
| Active conditions | Blindness of both eyes since childhood, comfortable; opioid use disorder in sustained remission |
| Functional status | Independent in all daily activities using nonvisual methods |
Health risk assessment. Read aloud by the nurse in a private room and answered by the patient himself; his answers were entered directly, and a copy was sent to him as an accessible electronic document. [S]
| Domain | Finding |
|---|---|
| Self-rated health | Very good |
| Psychosocial | Busy with work he loves; close long-time colleagues and friends; no loneliness |
| Substance use | No opioid or other drug use for more than thirty years (DAST-10 0); AUDIT-C 2; no tobacco |
| Physical activity | Walks daily with a sighted guide outdoors and on a treadmill at home |
| Nutrition | Regular meals; eats out often when traveling |
| Sleep | About seven hours a night, irregular when touring |
| Activities of daily living | Independent |
| Instrumental activities of daily living | Independent using a screen reader and voice assistant; staff help with travel arrangements |
| Home safety | Furniture kept in fixed places; doors and drawers kept closed or fully open; smoke detectors with voice alerts working |
| Falls | No falls this year; no fear of falling |
| Hearing and vision | Blind since childhood; relies on his hearing and has no hearing concern |
| Safety | Wears a seat belt; no firearms in the home |
| System | Result | Finding |
|---|---|---|
| Constitutional | Negative | Weight stable; no fever, night sweats, or fatigue |
| Eyes | Negative | No eye pain, redness, discharge, or headache around the eyes |
| Ears, nose, mouth, and throat | Negative | No hearing change, ringing, or ear pain |
| Cardiovascular | Negative | No chest pain, palpitations, or ankle swelling |
| Respiratory | Negative | No cough or breathlessness |
| Gastrointestinal | Negative | No abdominal pain, change in bowel habit, or blood in the stool |
| Genitourinary | Negative | No urinary symptoms |
| Musculoskeletal | Negative | No joint or back pain |
| Integumentary | Negative | No new or changing skin lesions that he has felt |
| Neurological | Negative | No headache, numbness, weakness, or memory concern |
| Psychiatric | Negative | Mood good; no cravings; no thoughts of suicide or self-harm; PHQ-2 score 0 |
| Endocrine | Negative | No thirst or frequent urination |
12 systems reviewed. [S]
| Medication | Frequency | Route | Dates | Status | Evidence |
|---|---|---|---|---|---|
| Naloxone 4 mg nasal spray, one spray in one nostril for a suspected opioid overdose; may repeat every 2 to 3 minutes in alternating nostrils | One spray (4 mg) in one nostril for suspected overdose; repeat every 2 to 3 minutes if there is no response, and call 911 | Nasal route | 1996-03-03 | active | S |
| Allergy | Reaction | Status | Evidence |
|---|---|---|---|
| No known allergy | active | S |
| Date | Measure | Value | Unit | Provenance |
|---|---|---|---|---|
| 1996-10-06 | Body height | 178 | cm | S |
| 1996-10-06 | Body weight | 80.4 | kg | S |
| 1996-10-06 | Body mass index (BMI) [Ratio] | 25.4 | kg/m2 | S |
| 1996-10-06 | Systolic blood pressure | 126 | mm[Hg] | S |
| 1996-10-06 | Diastolic blood pressure | 78 | mm[Hg] | S |
| 1996-10-06 | Heart rate | 68 | /min | S |
| 1996-10-06 | Respiratory rate | 14 | /min | S |
| 1996-10-06 | Body temperature | 36.7 | Cel | S |
| 1996-10-06 | Oxygen saturation in Arterial blood by Pulse oximetry | 98 | % | S |
| Date | Measure | Value | Unit | Reference range | Flag | Provenance |
|---|---|---|---|---|---|---|
| 1996-10-06 | Patient Health Questionnaire 2 item (PHQ-2) total score [Reported] | 0 | {score} | S | ||
| 1996-10-06 | Total score [AUDIT-C] | 2 | {score} | S | ||
| 1996-10-06 | Total score [DAST-10] | 0 | {score} | S |
Vital signs recorded on 1996-10-06; see the Vital Signs section. [S]
| System | Finding |
|---|---|
| Constitutional | Alert, warm, and witty; weight 80.4 kg, BMI 25.4. Each step of the examination described to him before it was done |
| Eyes | Dark glasses removed with his permission. No light perception. Lids and ocular surfaces quiet, with no redness, swelling, or discharge |
| Ears | Canals and tympanic membranes normal; whispered voice heard on both sides |
| Neck | No thyroid enlargement or nodes |
| Cardiovascular | Regular rhythm at 68 per minute; no murmur; no edema |
| Respiratory | Clear to auscultation bilaterally |
| Abdomen | Soft and non-tender; no masses or organ enlargement |
| Skin | No suspicious lesions |
| Musculoskeletal | Timed Up and Go 10 seconds, walking independently after a spoken orientation to the room; steady gait |
| Neurological | Fluent conversation; recalled three of three words after a delay; no focal deficit. Cognitive function assessed by direct observation and a verbal recall task, because the clock-drawing part of the Mini-Cog is not valid for a blind patient |
| Psychiatric | Euthymic; judgment and insight intact |
| Problem | Clinical status | Verification | Code | Provenance |
|---|---|---|---|---|
| Blindness of both eyes since childhood, no light perception; cause never diagnosed | active | confirmed | H54.0X55 | S — Synthetic modern coding of the documented childhood blindness; category 5 (no light perception) is a synthetic grading of what the sources call blindness. |
| Opioid use disorder (heroin), in sustained remission for more than thirty years, without medication treatment | active | confirmed | F11.21 | S — Synthetic modern coding of the publicly admitted heroin addiction and his documented recovery; listed as an active problem because it is managed at every visit, with remission carried by the code. |
Personalized prevention plan. A written copy was given to the patient. [S]
| Service | Status | Detail |
|---|---|---|
| Influenza vaccine, this season | Completed today | High-dose vaccine given today |
| Pneumococcal vaccine | Completed today | PCV20 given today; none on record |
| Recombinant zoster vaccine | Due | Two-dose series recommended; first dose at the next visit |
| COVID-19 vaccine, this season | Due | Recommended at 65 and older; he will get it at his pharmacy |
| Tetanus, diphtheria, and pertussis booster | Due | No dose on record in the past ten years; with the first zoster dose |
| RSV vaccine | Not indicated | Recommended at 75 and older, and from 50 with conditions that raise risk, which he does not have; review yearly |
| Depression screening | Completed today | PHQ-2 score 0, read aloud; PHQ-9 2 at the six-month review |
| Unhealthy alcohol use screening | Completed today | AUDIT-C score 2, below the risk threshold, read aloud |
| Unhealthy drug use screening | Completed today | DAST-10 score 0 for the past year, read aloud; sustained remission |
| Hepatitis C, hepatitis B, and HIV testing | Ordered | Recommended once for all adults and for people with a past substance use disorder; no prior result on record; drawn today with his consent, and results to be sent to him in an accessible format |
| Cognitive assessment | Completed today | Direct observation and a verbal three-word recall (3 of 3); the clock-drawing task is not used for a blind patient |
| Falls prevention | Completed today | No falls; Timed Up and Go 10 seconds; home layout kept fixed; sighted guide in unfamiliar places |
| Hearing | Completed today | No concern; whispered voice heard on both sides. Hearing is his main way of finding his way, so any change should be checked promptly |
| Vision and eye care | Up to date | Blind since childhood; ophthalmology examination in the spring; yearly review |
| Blood pressure screening | Completed today | 126/78 mmHg |
| Cholesterol and statin decision | Completed today | LDL 110 mg/dL at intake. Ten-year risk about 13 percent, but with no diabetes, hypertension, dyslipidemia, or smoking the criteria for a statin are not met; discussed, and he chose not to start one; revisit yearly |
| Diabetes screening | Up to date | HbA1c 5.5 percent at intake |
| Colorectal cancer screening | Ordered | No prior screening on record. He chose a yearly fecal immunochemical test; the kit's instructions were given as an audio file and the kit has tactile markers. A positive test needs colonoscopy |
| Prostate cancer screening | Declined | Shared decision-making about the small benefit and the risks of overdiagnosis; he chose not to have PSA testing |
| Lung cancer and abdominal aortic aneurysm screening | Not indicated | No tobacco use on record |
Immunizations given today: High-dose influenza vaccine, 1996-1997 season; Pneumococcal conjugate vaccine PCV20 [S]
Guideline basis: VA/DoD Clinical Practice Guideline for the Management of Substance Use Disorders (2021); CMID: Clinical Monitoring Intelligence Database, glaucoma and depression, bipolar, and mood disorders monographs (2026); Medicare Wellness Visits (Medicare Learning Network) (2026); Medicare Preventive Services reference: visit templates, screening cascades, and documentation elements (2026)
Follow-up: Chronic-care review in three months, with the first zoster dose and the Tdap booster. Test results sent to him as accessible electronic messages. Yearly ophthalmology review in the spring. Next annual wellness visit in one year. [S]
Voluntary advance care planning discussion of about 20 minutes, with his consent. He named a health care agent, and a health care proxy form was completed; the agent is recorded in the chart and is not named here. The form was read aloud to him in full before he signed it, and he was given an accessible electronic copy. He said that what matters most to him is staying independent, keeping up his work, and protecting his recovery, and that he wants to be asked directly, not through others, about any medicine that could affect it. He chose not to record specific treatment preferences today. The plan will be revisited yearly or after any serious illness. [S]